<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> therapy in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> is a controversial issue </plain></SENT>
<SENT sid="1" pm="."><plain>It is uncertain, whether <z:chebi fb="5" ids="28304">heparin</z:chebi> has a therapeutic or preventive effect in the early phase of the <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>From 1984-1989, 1095 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> were treated, 141 (12.9%) of whom received <z:chebi fb="5" ids="28304">heparin</z:chebi> within 3 days of <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The mean duration of <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulation was 10 days </plain></SENT>
<SENT sid="4" pm="."><plain>In 28 cases (20%), <z:chebi fb="5" ids="28304">heparin</z:chebi> was used as antithrombotic agent (25/28 patients suffered a basilar <z:mp ids='MP_0006134'>artery occlusion</z:mp>, of whom 22 died) </plain></SENT>
<SENT sid="5" pm="."><plain>In 113 cases (80%), <z:chebi fb="5" ids="28304">heparin</z:chebi> was used in embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> to prevent recurrence (24% cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo>, 54% arterio-arterial embolism, and 22% embolism of unknown etiology) </plain></SENT>
<SENT sid="6" pm="."><plain>The rate of recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> in the early phase was 13% with a persistent deficit in 5.3% </plain></SENT>
<SENT sid="7" pm="."><plain>The results are comparable with those of other trials reported in the literature </plain></SENT>
<SENT sid="8" pm="."><plain>Only 2 patients had an anticoagulation-related haemorrhage with clinical deterioration </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> anticoagulation in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> is a low-risk therapy, but its preventive value has not yet been demonstrated </plain></SENT>
</text></document>